ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine in patients with frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.